These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 35706081)

  • 1. Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak.
    Lee CM; Park SW; Lee E
    Infect Chemother; 2022 Jun; 54(2):258-265. PubMed ID: 35706081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased
    Kim H; Jang YR; Lee JY; Ko JH; Lee JY; Cho S; Lee YD; Song J; Hyun M; Kim HA; Hwang S; Ryou S; Na YJ; Lee JY; Lee C; Lee NY; Shin S; Kwon KT; Kim JY; Peck KR
    Front Cell Infect Microbiol; 2023; 13():1192512. PubMed ID: 37256107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study.
    Noh HJ; Song JH; Ham SY; Park Y; Won HK; Kim SJ; Chung KB; Kim CK; Ahn YM; Lee BJ; Kang HR
    Medicine (Baltimore); 2023 Nov; 102(45):e35987. PubMed ID: 37960790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study.
    Choi SJ; Park SW; Lee E
    Infect Chemother; 2022 Mar; 54(1):91-101. PubMed ID: 35384421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant.
    Jang YR; Oh YJ; Kim JY
    Int J Infect Dis; 2023 May; 130():94-100. PubMed ID: 36623794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study.
    Hwang S; Lee NY; Nam E; Kim YK; Kim SW; Chang HH; Kim Y; Bae S; Jeong J; Shin JH; Jang G; Lee C; Kwon KT
    Infect Dis Ther; 2024 May; 13(5):1037-1050. PubMed ID: 38607524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study.
    Lee S; Lee SO; Lee JE; Kim KH; Lee SH; Hwang S; Kim SW; Chang HH; Kim Y; Bae S; Kim AS; Kwon KT
    Int Immunopharmacol; 2022 May; 106():108570. PubMed ID: 35168079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit].
    Markina UA; Fomina DS; Lebedkina MS; Kruglova TS; Chernov AA; Zagrebneva AI; Mutovina ZY; Karaulov AV; Alexeeva EI; Lysenko MA
    Ter Arkh; 2022 Jun; 94(5):675-682. PubMed ID: 36286968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea.
    Hong SI; Ryu BH; Hong KW; Bae IG; Cho OH
    Infect Chemother; 2022 Mar; 54(1):114-124. PubMed ID: 35384423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea.
    Lee JY; Bu SH; Song E; Cho S; Yu S; Kim J; Kym S; Seo KW; Kwon KT; Kim JY; Kim S; Ahn K; Jung N; Lee Y; Jung Y; Hwang C; Park SW
    Infect Dis Ther; 2023 Oct; 12(10):2417-2435. PubMed ID: 37833467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study.
    Jang YR; Oh YJ; Kim JY
    Curr Ther Res Clin Exp; 2022; 96():100675. PubMed ID: 35601976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.
    Streinu-Cercel A; Săndulescu O; Preotescu LL; Kim JY; Kim YS; Cheon S; Jang YR; Lee SJ; Kim SH; Chang I; Suh JH; Lee SG; Kim MR; Chung DR; Kim HN; Streinu-Cercel A; Eom JS
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac053. PubMed ID: 35295819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study.
    Chae G; Choi A; Lim S; Park S; Lee S; Ahn Y; Kim J; Ra S; Jegal Y; Ahn J; Park E; Jun J; Kwon W; Lee T
    Trop Med Infect Dis; 2022 Mar; 7(3):. PubMed ID: 35324598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
    Kim JY; Săndulescu O; Preotescu LL; Rivera-Martínez NE; Dobryanska M; Birlutiu V; Miftode EG; Gaibu N; Caliman-Sturdza O; Florescu SA; Shi HJ; Streinu-Cercel A; Streinu-Cercel A; Lee SJ; Kim SH; Chang I; Bae YJ; Suh JH; Chung DR; Kim SJ; Kim MR; Lee SG; Park G; Eom JS
    Open Forum Infect Dis; 2022 Aug; 9(8):ofac406. PubMed ID: 36043180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19.
    Kim T; Joo DH; Lee SW; Lee J; Lee SJ; Kang J
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study.
    Park S; Je NK; Kim DW; Park M; Heo J
    BMC Infect Dis; 2024 Sep; 24(1):871. PubMed ID: 39223456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
    Fomina DS; Lebedkina MS; Iliukhina AA; Kovyrshina AV; Shelkov AY; Andreev SS; Chernov AA; Dolzhikova IV; Kruglova TS; Andrenova GV; Tukhvatulin AI; Shcheblyakov DV; Karaulov AV; Lysenko MA; Logunov DY; Gintsburg AL
    Front Immunol; 2023; 14():1259725. PubMed ID: 37928549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance.
    Kwak YG; Song JE; Kang J; Kang J; Kang HK; Koo HK; Park HK; Choi SB; Lee HP; Lee MJ; Kim BN
    Infect Chemother; 2022 Dec; 54(4):781-786. PubMed ID: 36226346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease.
    Lee JY; Lee JY; Ko JH; Hyun M; Kim HA; Cho S; Lee YD; Song J; Shin S; Peck KR
    Front Immunol; 2021; 12():772320. PubMed ID: 34899724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study.
    Park S; Je NK; Kim DW; Park M; Heo J
    J Korean Med Sci; 2022 Apr; 37(13):e102. PubMed ID: 35380027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.